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Case report Late local recurrence of dermatofibrosarcoma 
protuberans in the skin of female breast
Dimitrios M Dragoumis*1, Leda-Aikaterini K Katsohi1, Ioannis K Amplianitis2 and Aris P Tsiftsoglou1
Abstract
Dermatofibrosarcoma protuberans (DFSP) of the breast is exceptionally obscure and late local recurrence of this entity 
on this site is even more uncommon. We describe such a case in a 48-year-old woman, who at the age of 35 had a 
DFSP excised from her right breast. Thirteen years later, she developed an ovoid mass in her right breast over the 
postsurgical scar area. Wide local excision of the tumor with generous tissue margin was performed and microscopic 
and immunohistochemical findings established the diagnosis of recurrent DFSP. No further treatment was 
administered and she remains well 18 months later, without tumor recurrence. We report an exceptionally rare case of 
local recurrence of DFSP in the female breast and discuss in detail the diagnostic and therapeutic implications of this 
pathology.
Introduction
Dermatofibrosarcoma protuberans (DFSP) is a relatively
uncommon neoplasm of the deep dermis and subcutane-
ous tissue with low-grade malignant potential. Although
DFSP may have been reported in the medical literature as
early as 1890, this entity was initially described by Darier
and Ferrand in 1924 and was referred as "progressive and
recurring dermatofibroma". In 1925, Hoffman delineated
the clinicopathologic features of this lesion, which he offi-
cially termed "dermatofibrosarcoma protuberans" [1].
The clinical behavior of DFSP is characterized by pro-
gressive local growth and a propensity for local recur-
rence. DFSP most commonly appears on the trunk and
the extremities and it frequently looks like a benign
lesion. When it occurs over the breast it can be difficult to
distinguish from a primary breast lesion. Recent findings
from the medical literature indicate that the mainstay of
treatment is wide local excision, although Mohs micro-
graphic surgery (MMS) emerges as an alternative
approach to the use of wide resection surgery with
tumor-free margins. The recurrence rate after local exci-
sion tends to decrease, as the excision margins increase.
Although wide excision of lesions located on the body
and upper extremities allows satisfactory aesthetic
results, the situation is quite difficult for sites, such as the
breast, where large excision may lead to severe cosmetic
deformities [2,3].
Our case highlights two noteworthy features. Firstly,
DFSP of the breast is unusual, despite the fact that the
trunk is the most common site involved. Secondly, our
case describes a late local recurrence of this entity. A
review of the literature reveals that only few late DFSP
recurrences have been documented. In a review of 115
cases of DFSP, Taylor and Helwig cited a single recur-
rence after 20 years, while Swan et al observed a late
recurrence of DFSP in the breast after 26 years [3]. To our
knowledge, this is the second case in the medical litera-
t u r e  r e g a r d i n g  a  l a t e  l o c a l  r e c u r r e n c e  o f  D F S P  i n  t h e
breast.
Case Report
A 48-year-old woman became aware of a non-tender,
ovoid mass in the medial upper quadrant of her right
breast. Despite having been aware of this lesion for six
months, she had not sought immediate medical treat-
ment. The lump seemed to be near to the skin surface
and was located in the middle of postoperative scar tis-
sue. The scar measured 3 × 2 cm and recently had
become stretched and nodular in consistency. Her family
history was unremarkable, as well as her medical history,
except from the fact that at the age of 35, she had a skin
lesion excised from the same site of her right breast,
which was reported as DFSP.
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On physical examination, the patient had a well-cir-
cumscribed, reddish, mobile, soft mass, approximately 2
cm in diameter, and was detected in the 12-o'clock posi-
tion above the right breast, on the scar tissue of previous
breast biopsy. A clinical diagnosis of locally recurrent
DFSP of the right breast was strongly suspected.
Breast ultrasonography confirmed the presence of a
superficial, solid, well-defined lesion on the right breast,
measuring 20 mm, with increased shadowing through
transmission, simulating a benign neoplasm (Figure 1).
Mammography was not eventually performed because of
patient's denial and lack of suspicious findings of breast
parenchyma pathology on clinical and ultrasound exami-
nation. Core biopsy was then recommended and the
biopsy specimen demonstrated oval to spindle-shaped
cells arranged in a storiform growth pattern suggestive of
DFSP. Staging investigations were subsequently per-
formed to exclude the presence of metastatic disease.
Preoperative examination consisting of a full blood count,
serum kidney and liver functions, chest X-ray, as well as
computed tomography (CT) of the chest, was within the
normal limits.
The necessity for radical surgical treatment was thor-
oughly discussed with the patient, who was markedly
concerned about the postoperative cosmetic result, fol-
lowing this second resection. The lesion was excised,
including a wide 3 cm margin of normal looking skin,
under local anesthesia and the defect was closed primar-
ily.
The histological essay showed a soft tissue neoplasm
comprising islands of spindle cells with plump nuclei and
indistinct cytoplasm. The lesion was located in the retic-
ular region of the dermis, causing expansion of subcutic-
ular interlobular septa with irregular extension of
spindle-cell component into adipose tissue lobule, but did
not infiltrate the overlying papillary region or the epider-
mis (Figure 2). Microscopic sections demonstrated a
tumor characterized by the presence of densely cellular
uniform spindle cells arranged in whorling fascicles with
a storiform pattern (Figure 3). This tumor was highly cel-
lular, but had relatively few mitoses.
The spindle cells within the dermis did not demon-
strate significant staining with antibodies directed against
fibrin-stabilizing factor XIII A, S-100 protein, smooth-
muscle actin or cytokeratins AE1/AE3. On the other
hand, the immunohistochemical profile of the tumour
included intense positivity for CD34 (Figure 4). These
histological and immunohistochemical findings therefore
established the diagnosis of recurrent DFSP.
Figure 1 Breast ultrasonography showing a superficial, solid, 
well-defined lesion with increased shadowing through transmis-
sion, simulating a benign breast neoplasm.
Figure 2 Histologic section of the breast tumor demonstrating ir-
regular extension of spindle-cell neoplasm (black arrows) into 
adipose tissue (Haematoxylin and Eosin stain; original magnifica-
tion × 100).
Figure 3 Higher-magnification photomicrograph showing bun-
dles of fairly uniform, spindle cells (black arrows), arranged in a 
prominent "storiform" or "cartwheel" pattern (Haematoxylin and 
Eosin stain; original magnification × 400).Dragoumis et al. World Journal of Surgical Oncology 2010, 8:48
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After surgery, the patient was proposed to receive
radiotherapy or even imatinib mesylate (800 mg/daily),
but eventually no adjuvant therapy was administered, due
to patient's desire for a "watchful waiting" tactic. Postop-
erative follow-up is satisfactory to date and 18 months
later the patient remains well, without any signs of tumor
recurrence.
Discussion
DFSP accounts for less than 0.1% of all malignancies and
approximately 1% of all soft tissue sarcomas. DFSP is a
locally aggressive tumor with a high recurrence rate.
Most recurrences of DFSP are detected within 3 years of
primary excision. Although metastasis of DFSP is rare
(approximately 1-4%), almost all metastatic cases have
been associated with local recurrence and a poor progno-
sis. Most of the patients with metastatic DFSP have died
within 2 years. The relative 5-year survival rate for DFSP
is 99.2% [1,2].
Among patients, the female to male ratio is 1:1 and the
lesions occur most frequently between the second to fifth
decades of life. Rarely, DFSP has been reported in new-
borns and elderly individuals (~80 years). It most com-
monly appears on the trunk (42-72%), followed by the
proximal extremities (16-30%). DFSP rarely occurs above
the neck (10-16%) and it is extremely uncommon on the
breast [4,5].
Clinically, these neoplasms usually present as a raised,
indurated, asymptomatic plaque that may be any combi-
nation of blue, red, and brown or flesh colored. The dif-
ferential diagnosis should always include delayed
hypertrophic scar formation, keloids, a recurrent der-
matofibroma, or possibly the cutaneous manifestation of
underlying 'spindle cell' breast diseases, including a spec-
trum of tumours with considerable histological similari-
ties, which often require immunohistochemical or even
ultrastructural study for accurate identification (fibroma-
tosis, myofibroblastoma, metaplastic carcinoma etc).
Chest radiography may be ordered for baseline screening
for pulmonary metastasis in high-risk cases, such as
recurrence or suspicion for a fibrosarcoma variant of
DFSP [2,3,6].
Histologically, the nodular form of DFSP is character-
ized by a proliferation of plump spindled cells arranged in
a monotonous storiform pattern. The cells have little
nuclear pleomorphism, and secondary elements such as
giant cells, siderophages and chronic inflammatory cells
are infrequent. The plaque form of DFSP, however, may
show little extension into the subcutaneous tissue and
mainly contains slender tumor cells with large, spindle-
shaped nuclei, embedded fairly uniformly in the collagen
stroma, parallel to the skin surface, while the mitotic fig-
ures are sparse. The degree of cellular atypia is higher in
nodular lesions than in plaque lesions. Occasionally,
DFSP may show focal fibrosarcomatous changes with a
characteristic herringbone pattern. The cellular atypia is
then even more prominent with hyperchromatic nuclei
and more mitotic figures. Histologic subtype, high
mitotic index, cellularity, size, location on the head and
neck, and recurrent lesions are factors reportedly associ-
ated with higher recurrence rates [5,7].
Immunohistochemical studies have shown moderate-
to-strong staining of human progenitor cell antigen CD34
in tumor cells. CD34 is a useful marker that allows differ-
entiation of DFSP tumor cells from normal stroma cells
and dermatofibroma (DF). In DF, tumor cells are positive
for factor XIIIa and are rarely positive for CD34. Addi-
tionally, immunostaining using CD34 as a marker is help-
ful in identifying tumor cells at the surgical margins,
particularly when treating recurrent DFSP, in which
tumor cell fascicles are often interspersed with the scar
tissue. Although CD34 and Factor XIIIa can differentiate
most cases of DFSP and DF, the overlap of CD34 and Fac-
tor XIIIa expression in both lesions indicates the need to
identify other potential immunohistochemical markers
[7].
Recently, Stromelysin-3 (ST3) was found to be a useful
marker for the differential diagnosis of DF and DFSP. ST3
is a member of the matrix metalloproteinase (MMP) fam-
ily, which is believed to play a role in tissue remodeling
during various processes, such as wound healing and
tumour invasion. ST3 is expressed in the majority of
cases of DF, whereas DFSPs are only rarely ST3 positive.
Tenascin is an extracellular matrix glycoprotein
expressed in fibroblasts and the extracellular matrix dur-
Figure 4 Diffuse, strong immunohistochemical staining for CD34 
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ing embryogenesis and growth. Several studies have
shown that there is increased expression of tenascin at
the dermal-epidermal junction overlying the spindle cell
proliferation in DF, but not in DFSP. Moreover, there is an
increasing body of evidence suggesting that DFSP arises
from mutated stem cells and demonstrate diffuse strong
positivity for the neuroepithelial stem cell protein, nestin.
Strong immunoreactivity for nestin is found in DFSP,
whereas all DF cases are nestin-negative [8-10].
Surgical excision remains the cornerstone of treatment
for DFSP. Complete surgical resection is accepted as the
optimal treatment for primary or recurrent DFSP. Most
authorities would suggest a margin of 2-3 cm of normal
tissue from the gross tumor boundary, with a three-
dimensional resection that includes skin, subcutaneous
tissue, and the underlying fascia. Despite optimal surgical
management, local and regional recurrences are detected
in up to 17% of patients with classic DFSP. When surgical
margins are inadequate or conservative, recurrence rates
increase [5,11].
Radiotherapy provides a useful adjunct, where ade-
quate margins cannot be easily obtained. Radiation can
be considered as a possible adjuvant to surgery i) if mar-
gins are positive or close after maximal resection, ii) if a
large lesion has been excised with negative margins, iii) if
there is concern about the adequacy of negative margins,
iv) if a recurrent lesion has been resected, or v) if the
achievement of wide margins would result in a functional
or cosmetic defect. The complete radiotherapy dose
ranges from 60-70 Gy [5,11,12].
Nowadays, Mohs micrographic surgery (MMS) has
been advocated by several authors as an alternative
approach to the use of wide resection surgery with
tumor-free margins. Mohs surgical technique allows an
immediate microscopic examination of the margins. The
process is repeated several times, until a clear margin is
achieved. Proponents of this surgical intervention suggest
it allows removal of asymmetrical tissue, thus enhancing
cosmetic result. In addition, a lower recurrence rate has
also been cited by those who recommend MMS as the
treatment of choice. However, larger studies and longer
follow-up will be necessary to confirm these findings
[5,11,13].
Most cases of DFSP feature a specific translocation of
chromosomes 17 and 22, which results in constitutive
production of platelet-derived growth factor B chain
(PDGFB) and stimulation of DFSP growth. This chromo-
some translocation t (17, 22) is detected in more than
90% of DFSP tumors. The collagen type I alpha 1-platelet-
derived growth factor beta (COL1A1-PDGFB) fusion is
present in all histological subtypes of DFSP, but not all
cases express the fusion transcript. Till now, no associa-
tion was observed between different COL1A1 break-
points and clinicopathological parameters. Imatinib
mesylate is a potent, selective inhibitor of PDGFR alpha
(PDGFRa), PDGFR beta (PDGFRb), BCR-abl, KIT, ARG
and c-FMS protein-tyrosine kinases [12,14]. In preclinical
studies, imatinib inhibited the growth of DFSP cells, as
well as fibroblasts transformed by the t (17; 22) chromo-
somal rearrangement both in vitro and in vivo. On Octo-
ber 19, 2006, the US Food and Drug Administration
(FDA) granted approval for imatinib, as a single agent for
the treatment of adult patients with unresectable, recur-
rent, and/or metastatic DFSP. With limited clinical data
to date, a response rate of approximately 65% has been
achieved among DFSP patients treated with imatinib
(recommended dose 800 mg/d). A small subset of DFSP
lacking the classic t (17, 22) gene aberration seems to
have no response to imatinib. Thus, cytogenetic studies
that confirm PDGFB gene rearrangement may be neces-
sary in predicting future clinical response, prior to ima-
tinib therapy administration [5,11,15,16].
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